SBIR/STTR Research Award

MODIFIED NUCLEOSIDES IN TRIPLEX FORMING OLIGONUCLEOTIDES

Award identifier 0a92ef03d5eb43b3391a2bd40e875d2ba5e28803d31c8a0dfe037232da2c1cbcAwarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1992

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Triplex Pharmaceutical
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

THE PRIMARY GOAL OF THIS STUDY IS TO CHEMICALLY REFINE A CLASS OF SEQUENCE-SPECIFIC, DNA BINDING, TRIPLE HELIX-FORMING OLIGONUCLEOTIDES (TFOS). THE UNIQUE FEATURE OF THESE TFOS IS THAT BINDING OF THE THIRD STRAND TO ITS DUPLEX DNA TARGET IS PH INDEPENDENT AND IS STABILIZED BY GGC AND TAT TRIPLETS SUCH THAT THE PREFERRED ORIENTATION PLACES THE BOUND TFO ANTIPARALLEL WITH RESPECT TO THE MORE PURINE RICH STRAND OF THE UNDERLYING DUPLEX. IN ACCORD WITH MOLECULAR MODELING, 2'-DEOXYFORMYCI (DF) IS INTRODUCED INTO 3'-AMINE MODIFIES TFOS AT SITES ENGAGED IN H-BONDING WHERE POLYPURINE/POLYPRYIMIDINE RUNS IN A DUPLEX TARGET ARE INTERRUPTED BY A CG INVERSION. THE BINDING AFFINITY OF SUCH A DF-TFO IS ASSESSED BY BAND SHIFT ANALYSIS AND BY QUANTITATIVE DNASE I FOOT-PRINTING TECHNIQUES. THE EFFECT OF DF UPON TRIPLEX STRUCTURE IS ASSESSED BY LOCAL HIGH AFFINITY CUPHENANTHROLINE CLEVAGE. IN PRELIMINARY STUDIES, A HOMOLOGUE OF 3'A-PRE2AP DISPLAYED A 10-FOLD INCREASE IN BINDING AFFINITY DUE TO INCLUSION OF DF AT THREE SITES AS COMPARED TO ITS UNMODIFIED COUNTERPART. IN PHASE I STUDIES WE WILL CONFIRM THESE FINDINGS AND EXTEND THE USE OF DF SUBSTITUTION WITHIN TFOS WHICH ARE SPECIFIC FOR EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) (EG36AP), MOUSE INSULIN RECEPTOR (IR) PROMOTER (IR2AP) AND HIV-1 (HIV38P) DOMAINS. IF DF SUBSTITUTION IMPROVES TRIPLE HELIX STRUCTURE AND BINDING AFFINITY, IN PHASE II STUDIES THE BIOLOGICAL EFFECTS OF SUCH TFOS WILL BE ASSESSED.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.